

Flumazenil

CAUTION: High Administration Risk Rating		
Form	500 microgram (0.5mg) per 5mL ampoule	Store below 25°C
Reconstitution	Already in solution <ul style="list-style-type: none"> • Draw up using a 5 micron filter needle • Use gloves when opening ampoules 	
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5%	
Administration	IV Injection	
	Administer slowly over 15 seconds into a large vein.	
	Continuous IV Infusion Dilute to a concentration of 10 microgram/mL e.g. 500 microgram in 50mL 2.5mg in 250mL Give using an infusion pump, adjusting rate according to response. Stop infusion every 6 hours to check whether re-sedation occurs. Preferably administer via a central venous access device to avoid potential venous irritation. If given peripherally, choose a large vein and monitor the injection site closely.	
Extravasation	Extravasation is likely to cause tissue damage because of extreme pH (less than 5).	
Additional Information	<ul style="list-style-type: none"> • Flumazenil should only be administered by, or under the direct supervision of, personnel experienced in its use. • Half-life is very short (40-80 minutes), therefore an infusion may be necessary if drowsiness returns after a single dose. • See Toxbase (username/password required, available Resusc room ED) 	

Information provided relates to Anexate® (Cheplapharm Arzneimittel GmbH) and Flumazenil (Baxter)